Jetrea Approved to Treat Eye Condition
THURSDAY, Oct. 18 (HealthDay News) -- Jetrea (ocriplasmin) has been approved by the U.S. Food and Drug Administration to treat an eye condition called symptomatic vitreomacular adhesion (VMA).
The condition affects the vitreous, a jelly-like substance in the center of the eye, which begins to separate from the macula. This can damage the macula, a key part of the eye's retina that's responsible for people being able to read, the FDA said Thursday in a news release.
Jetrea helps break down proteins that are responsible for VMA, preventing the need for surgery to control the condition, the agency said.
In a clinical study of 652 people, VMA resolved in 26 percent of those who took Jetrea, compared to 10 percent of cases that were resolved among those who took an inactive placebo.
The most common side effects of Jetrea were eye problems including: bleeding, pain, floaters, blurriness, vision loss and swelling.
Jetrea is produced by ThromboGenics, based in Iselin, N.J.
The FDA has more about this approval.Related Articles
- FDA Advisory Panel Says Steroid Shots for Back Pain Can Continue
November 25, 2014
- Abuse-Resistant Prescription Painkiller Approved
November 20, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2012 HealthDay. All rights reserved.